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Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA).
However, after more than a decade of controlled studies, no deﬁnitive consensus has been reached regarding clinical eﬃcacy.
Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by
meta-analyses, the more recent reports lacked the provision of deﬁnitive response in terms of hard clinical endpoints.
Regrettably, pivotal trials designed to conclusively determine the eﬃcacy of cell-based therapeutics in such a challenging clinical
condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA
seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed.
As an example, the large variability in eﬃcacy endpoint selection appears to be a limiting factor for the advancement of
cardiac cell-based therapy in the ﬁeld. This review will provide an overview of the key elements that may have inﬂuenced
the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of
angina-related endpoints may predict cell-based therapeutic eﬃcacy.
1. Introduction
Refractory angina (RA) is a chronic condition characterized
by the presence of persistent angina or angina equivalents
(≥3 months) caused by untreatable coronary artery disease
(CAD) in patients with objective evidence of myocardial
ischemia [1]. The presence of left ventricular (LV) dysfunction
may worsen such a clinical scenario. Refractory angina
patients are deﬁned as being “no option” since they are
deemed not amenable for conventional revascularization
treatment for reasons related to diﬀuse coronary lesions,
unsuitability to chronic total occlusion mechanical revascu-
larization, or frailty from the presence of severe comorbidities.
These pathological featuresmay signiﬁcantly aﬀect the quality
of life with regard to physical function and well-being as well
as midterm fatality [2], although the most recent reports have
documented a time-dependent increase inmortality rates (less
than 4% at 1 year and 30% at 9 years) [3]. Outcome ameliora-
tions have been ascribed to rigorous adoption of standard
medical therapy, risk factor modiﬁcation, and aggressive
revascularization techniques [4]. Nevertheless, despite con-
tinuous advances in CAD management, particularly in the
aged population, the number of patients suﬀering from RA
and the correlated hospitalization costs are still growing [5].
In fact, available estimates suggest that RA aﬀects between
600,000 and 1.8 million people in the USA with an incidence
of 50,000 [5] and 30,000–50,000 new cases per year in the
USA and continental Europe, respectively [6].
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It is important to highlight that the medical care of these
patients is particularly challenging. As a matter of fact, the
therapeutic options and available directions from current
guidelines are still limited [6]. Moreover, the interaction
between clinical symptoms, myocardial perfusion abnormal-
ities, coronary anatomy, and ventricular function are partic-
ularly complex in these individuals. Thus, novel treatments
for RA management in patients nonresponsive to standard
pharmacologic therapies and not amenable to mechanical
revascularization procedures are evermore needed.
In this regard, recent eﬀorts have been directed on the
discovery of novel therapies based on innovative interven-
tional techniques, neuromodulation, shockwave strategies,
and cell-based interventions. In particular, in the analogy
of other high-impact cardiac conditions as left ventricular
dysfunction following ST-elevated acute myocardial infarc-
tion and chronic heart failure, cardiac cell-based therapy
has emerged as a promising tool for the management of
RA [7]. The application of cardiac cell-based therapy in
this patient population was described for the ﬁrst time in
2003 by Tse and coworkers [8]. After this preliminary
experience, several uncontrolled and controlled phase I-II
trials were conducted. Collectively, published studies have
overtime demonstrated the safety and potential beneﬁt
of diﬀerent cell types. In an attempt to shed light on
the available results, 3 meta-analyses have speciﬁcally
addressed cardiac cell-based therapy eﬃcacy in RA [9–11].
Notably, the most recent work by Khan et al. [11], cumu-
latively taking into account 6 controlled trials with 365
enrolled patients, clearly showed that cardiac cell-based
therapy has had a positive impact over standard of care
in terms of myocardial perfusion, angina frequency, use
of antianginal medications, change in the Canadian func-
tional class, exercise tolerance, LV function, and major
adverse cardiac events (MACE). Notably, 3 large rigorous
clinical trials have been recently made available [12–14].
Unfortunately, the outcomes reported in these studies were
not conclusive due to early discontinuation, for example,
the regrettable decision on the behest of the study sponsor
to prematurely stop the phase III RENEW trial which was
suﬃciently powered to deﬁnitively evaluate the safety and
eﬃcacy of intramyocardial injection of CD34+ cells in
“no option” RA patients.
In the light of these and other inconclusive results
[15, 16], a reappraisal of the therapeutic eﬃcacy of cardiac
cell-based therapy in RA seems imperative. In particular, a
number of crucial aspects, including rigorous trial design,
sample size, and endpoint assumptions, deserve to be care-
fully reconsidered. As an example, the huge discrepancy in
the choice of endpoints probably represents the more
relevant limiting factor for the lack of eﬃcacy demonstration.
In this work, we have provided an updated overview of
the results stemmed from available clinical trials focused
on the role of cardiac cell-based therapy for the manage-
ment of RA. Furthermore, we have comprehensively dis-
cussed ischemia-related outcomes, including objective and
subjective endpoints, in order to facilitate a critical reap-
praisal of published studies on cardiac cell-based therapy
for RA.
2. Overview of Cardiac Cell-Based Therapy
Clinical Trials in RA
To date, twenty-six cell-based therapy trials have been
conducted in the context of RA (see Table 1). Key aspects,
including the number of patients treated, cell sources and
types, baseline ejection fraction, delivery methods, and eﬃ-
cacy and safety outcomes, have been collected and analysed
hereafter. As for the concomitance of LV dysfunction, when
available, baseline EF below normal and/or the proportion
of patients with LV impairment has been highlighted.
It is worth to mention that safety of cardiac cell-based
therapy, deﬁned as related serious adverse events (SAEs)
and/or major adverse cardiac events (MACE) occurring
during cell delivery, hospitalization, and follow-up, appears
to be overall reassuring as for available studies.
2.1. Study Design. A signiﬁcant proportion of published trials
(n = 13) may be categorized as uncontrolled pilot or phase I
studies that cumulatively enrolled 220 patients (21% of the
entire accrual population), ranging from a minimum of 4 to a
maximum of 38 subjects [8, 19–23, 26, 28, 29, 31, 33, 36, 39].
A total of 841 patients have been included in phase II ran-
domized controlled trials (RCTs; n = 13) [12–17, 24, 30,
32, 34, 35, 40, 41]. The vast majority of these RCT reported
the adoption of an appropriate placebo or saline group
[13, 14, 17, 30, 34, 35, 38, 41, 42]. However, some other
studies (for instance FOCUS-HF and PROGENITOR trials),
in an attempt to overcome ethical and practical obstacles of a
placebo group, employed alternative methodologies such as
sham and mock injection procedures [15, 24]. To our
knowledge, large conﬁrmatory phase III studies are not
yet available. The mean follow-up was 12 months (range:
3–36 months). Merely 23% of studies were able to prolong
postoperative surveillance beyond 1 year.
2.2. Cell-Related Variables. Selected or unfractioned cells,
primarily derived from the bone marrow (BM) [8, 13, 16,
19–24, 26, 28–33, 35, 36, 39–41] and to a lesser extent from
peripheral blood (PB) [15, 17, 38] and, more recently, from
the adipose tissue (AT), have been tested for their therapeutic
potential in RA [14, 34]. Speciﬁcally, mononuclear cells
(MNC), endothelial progenitor cells (such as CD34+ and
CD133+ cells), and mesenchymal cells (MSC) have been sub-
sequently investigated (Figure 1). It is worth highlighting that
a direct comparison of diﬀerent cell types is unfortunately
not available. Notably, BM-derived MNC, the most exten-
sively delivered cell type, have an unambiguously proven
safety proﬁle in the early and long-term period. Available
data further suggested that BM-MNC therapy seemed
eﬀective in ameliorating myocardial perfusion and angina
frequency [31, 42]. Moreover, the group of Mann et al. [31]
showed that repeated BM cell injections in previously
responding patients can reinforce clinical improvements.
To date, such “ﬁrst generation” cell lines have not been
followed by more advanced “next generation” cell therapeu-
tics. For instance, allogeneic applications, which have pro-
vided positive outcomes for other pathologic cardiac
conditions [43–45], have not yet been explored in RA to date.
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Likewise, the so-called “second generation” stem cells,
consisting of more puriﬁed cell populations, such as cardiac
stem cells (CSC), cardiosphere-derived cells, or combination
of cells (MSC/CSC or MSC/macrophage lineages), have not
yet been examined in RA. Cumulatively, the big picture of
on-going studies suggests that new early studies are still
pursuing the path of autologous BM-MNC (Figure 1).
As for cell dose, unlike other cardiac settings, it has to be
mentioned that there is a plethora of dose-escalation trials
already available [14, 17–19, 29, 30, 35]. Most of these studies
concerned PB-derived CD34+ cell dose ﬁnding, thanks to the
eﬀort of Losordo and coworkers [30]. Once veriﬁed in early
safety of intramyocardial injection of 50,000 CD34+ cells/kg,
in the subsequent phase IIb ACT34-CMI study, they com-
pared the eﬃcacy of two escalating dosages of CD34+ cells
(1× 105 and 5× 105). Surprisingly, patients treated with the
low dosage experienced greater improvements in angina fre-
quency and exercise tolerance at 6 and 12 months, [17]. Nev-
ertheless, after 24 months of follow-up, reduction in angina
frequency was equivalent in both cell groups (p = 0 03) [18].
Additionally, Lee et al. [29] recently reported the superiority
of 1× 107 cells with respect to 3× 107 CD34+ cells in improv-
ing heart function and clinical symptoms in patients with
untreatable myocardial ischemia and LV dysfunction.
The dose-dependent response of BM-MNC has been fur-
ther investigated in the PROTECT-CAD study [35] in which,
however, no signiﬁcant diﬀerence between the low- (1× 106
cells/0.1mL) and the high-dose groups (2× 106 cells/0.1mL)
was observed in terms of total exercise time at 6 months of
follow-up compared to baseline.
Therefore, based on currently available studies, there is
no clear evidence of a dose-dependent eﬀect of BM-derived
cell delivery in RA patients. Further studies are thus neces-
sary to completely address this question.
2.3. Cell Delivery. The injection technique is certainly a criti-
cal factor for the success and optimization of cell therapeu-
tics. To date, a noticeable proportion of cardiac cell-based
therapy trials in RA (n = 18) utilized advanced catheter-
based endocavitary transendocardial cell administration
strategy [8, 13–17, 21–26, 30–32, 34, 35, 38]. In this regard,
the NOGA electromechanical mapping system has been
proposed as an eﬀective and reliable percutaneous method
capable of discriminating between viable myocardium and
scar tissue to precisely guide cell delivery into the target
territories of the left ventricle. On the other hand, the
ﬂuoroscopy-guided strategy brings cost advantages and
wider accessibility. In both cases, procedural safety has been
consistently conﬁrmed. Recently, in the context of the Phase
I Trial of Endocavitary Injection of Bone Marrow Derived
CD133+ Cells in Ischemic Refractory Cardiomyopathy
(RECARDIO trial, NCT02059681), we have proposed a
novel approach based on the integration of 3-dimensional
(3-D) electroanatomical mapping (CARTO) with real-
time intracardiac echocardiography (ICE) to guide the
ﬂuoroscopy-based infusion catheter [46].
Other delivery approaches included intracoronary
[19, 29, 41] and intravenous infusion [39] and direct epicar-
dial injection by open-chest surgery [20, 28, 33, 36].
Although no comparative studies are available to ascertain
the most eﬀective delivery option in RA, it appears that intra-
myocardial cell inoculation was by far the preferred delivery
method in such a clinical context.
2.4. Eﬃcacy Outcomes. A wide spectrum of surrogate eﬃcacy
endpoints has been proposed to evaluate the eﬃcacy of cell
therapy in the RA setting, including indices of angina severity
(Figure 2), as well as myocardial perfusion, exercise capacity,
and cardiac function evaluations (Figure 3).
2.4.1. Angina Assessment. As for the assessment of angina,
the Canadian Cardiovascular Society (CCS) classiﬁcation
score (Figure 2(a)) was employed in the vast majority of
available studies (n = 23). Notably, 78% of these trials
reported a signiﬁcant improvement in CCS angina class after
cardiac cell-based therapy. Importantly, 24% of trials have
described an improvement of CCS greater than 2 classes in
cell-treated patients (Figure 2(b)). As an example, the ran-
domized, placebo-controlled trial by Wang and coworkers
[41] has described a remarkable reduction in CCS class from
3.3± 0.5 at baseline to 0.9± 1.0 at 6 months after intramyo-
cardial delivery of CD34+ cells.
As an alternative evaluation, the number of anginal
episodes per week as well as nitroglycerin (NTG) consump-
tion has been proposed as valuable eﬃcacy endpoints to
describe changes in angina severity. Remarkably, in line with
changes observed in CCS class, almost all studies reported
ameliorations in terms of reduction in angina frequency
and antianginal medications (Figures 2(c) and 2(d)). In this
regard, the ACT34-CMI trial [17] suggested positive out-
come beneﬁts lasting over 2 years following intramyocardial
administration of BM-derived CD34+ cells [18].
2.4.2. Quality of Life and Health Status Evaluation. Patients’
quality of life and health status have been investigated as
pertinent variables strictly associated with angina severity.
CD34
n = 3
CD133
n = 2
N°
Trials
Phase I Phase II
MNC
n = 8
CD133
n = 4
MNC
n = 5
CD34
n = 1
MSC
n = 1
MSC
n = 2
Figure 1: Cell types applied in clinical trials to treat RA. The ﬁgure
depicts the number of published studies sorted for cell types and
trial phases. MNC: mononuclear cells; MSC: mesenchymal stem
cells; CD: cluster of diﬀerentiation.
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By the use of dedicated surveys, many studies docu-
mented a positive impact of cardiac cell-based therapy
in terms of quality of life improvements. For instance,
the FOCUS-HF trial adopted the Minnesota Living with
Heart Failure and the Short Form-36 questionnaires to
evaluate at 6 months over baseline the quality of life
improvements in cell-treated and control patients [24].
In both questionnaires, patient scores improved only in
the cell-treated group (p = 0 009 and p = 0 002, resp.). Other
studies documented the changes in the quality of life using
the disease-speciﬁc Seattle Angina Questionnaire (SAQ).
Consistently, both Henry et al. [18] and van Ramshorst et
al. [40] showed a signiﬁcant increase in SAQ scores in these
patients at 6 and 12 months.
2.4.3. Myocardial Perfusion Assessment. Changes in regional
myocardial perfusion were usually assessed by single-
photon emission computed tomography (SPECT) imaging,
with the aim to provide semiquantitative scores of the sever-
ity and extent of the perfusion defect. Speciﬁcally, changes in
summed stress score (SSS), summed rest score (SRS), and
summed diﬀerence score (SDS) were measured between the
ends of follow-up and baseline. Remarkably, 24 out of 26
analysed trials were able to report a SPECT perfusion
endpoint (Figure 3(a)). Overall, a signiﬁcant percentage of
studies (58%) suggested that the therapeutic delivery of cells
leads to an objective improvement in myocardial perfusion.
It is however worth mentioning that a considerable pro-
portion of positive outcomes stemmed from uncontrolled
phase I trials which enrolled a limited number of patients
[8, 19–23, 31, 33, 36, 39]. Convincingly, positive data were
also reported by more rigorous RCT [17, 40, 41], includ-
ing the ACT34-CMI trial [17], which showed at 6 months
of follow-up a signiﬁcant improvement of the SSS in the
cell group but not in controls (−117.4± 221.2 versus
+ 0.1± 161.1, p = 0 002). Conversely, disappointing ﬁndings
arose from the recently published REGENT-VSEL [13]
and ATHENA trials [14]. The latter randomized, double-
blind study that enrolled in 1 : 1 ratio 31 patients versus
controls failed to uncover statistical signiﬁcant diﬀerences
in SPECT parameters. Taken together, these ﬁndings sug-
gest the need for an implementation and standardization
of alternative methodologies, including positron emission
computed tomography (PET) or cardiac magnetic reso-
nance (cMR) imaging, to deﬁnitively document changes
in regional and global myocardial perfusion at a microvas-
cular level [17, 41].
2.4.4. Functional Capacity Evaluation. As for functional
capacity assessments, various objective endpoints were pro-
posed, taking advantage of exercise testing with or without
ventilatory gas exchange measurements. A variety of indica-
tors was analysed, including exercise time, walking distance,
maximal O2 consumption (MVO2), and other metabolic
equivalents (METs). Cumulatively, such surrogate endpoints
were reported to be positive in the majority of RCT, includ-
ing the PROTECT-CAD [35], ACT34-CMI [17], ATHENA
[14], and RENEW [12] trials (Figure 3(b)). In particular,
78%
22%
CCS class (n = 23)
Positive
Negative
(a)
24%
76%
CCS class ≥ 2 (n = 17)
CCS ≥ 2
CCS ≥ 1
(b)
87%
13%
Angina frequency (n = 15)
Positive
Negative
(c)
70%
30%
NTG use (n = 10)
Positive
Negative
(d)
Figure 2: Indices of angina severity used to evaluate the eﬀect of cardiac cell-based therapy in patients with RA. This schematic representation
provides an analysis of the improvements observed in clinical trials relative to CCS class (a), CCS class greater than 2 (b), angina frequency (c),
and nitroglycerine use (d). Positive and negative study outcomes have been deﬁned according to statistical signiﬁcance. The number of studies
in the analysis is indicated between brackets. CCS: Canadian Cardiovascular Society; NTG: nitroglycerin.
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the RENEW trial [38], the larger phase III study compar-
ing intramyocardial delivery of CD34+ cells with respect to
two control groups (placebo and standard care), was
designed to detect changes in total exercise time (TET)
at 12 months in 400 untreatable RA patients. Although
the enrolment was prematurely stopped by the sponsor
after the ﬁrst 112 patients, study results, made recently
available [12], showed the superiority of the cell therapy-
treated patients compared with controls in improving
TET (139 s± 115 versus 69 s± 122 s; p = 0 01). On the con-
trary, two consecutive reports by Perin et al. [16, 24]
described the lack of MVO2 improvements in patients
receiving BM cell therapy versus placebo, with the excep-
tion of a young patient subset (≤60 years). However, func-
tional ﬁndings described here, when taken cumulatively,
should be examined with caution since possible shortcom-
ings, such as a wide heterogeneity of endpoints and the
intrinsic limitations of such functional tests (e.g., subject
compliance, orthopedic, or lower limb deﬁciencies), may
have conditioned the outcomes.
Nevertheless, along with angina-related and perfusion
endpoints, functional capacity assessments may play an
important role in the context of future cardiac cell-based
therapy studies in RA. Much eﬀort should be given to the
methodology for isolating improvements as well as for sam-
ple size selection. In this regard, from a methodological and
regulatory standpoint, it is valuable to note that the mindful
and weighted combination of the aforementioned indicators
may oﬀer a unique opportunity to provide eﬃcacy evidence
with relatively limited patient sample sizes.
2.4.5. Global and Regional Cardiac Function Assessment.
Cardiac cell-based therapy eﬀects have been assessed by
measuring global and regional cardiac function before
and after cell administration. A variety of imaging meth-
odologies with diﬀerent acquisition and analysis protocols
was applied. In the RA setting, left ventricular ejection
fraction (LVEF) and volumes were assessed by cMR in
7 studies [8, 13, 28, 31, 34, 35, 40], by echocardiogram
in 6 studies [14, 16, 22, 32, 33, 37], by SPECT in 4
studies [21, 23, 26, 39], and by combining diﬀerent modali-
ties in further 4 studies [15, 20, 24, 29]. In regard to LVEF
changes, a signiﬁcant number of studies (52%) revealed a lack
of improvements at diﬀerent follow-up time points
(Figure 3(c)) [8, 13–15, 22–24, 31, 33, 34, 36]. In particular,
when limiting the analysis to cMR evaluations, the majority
of published studies were negative [8, 13, 28, 31, 34, 35, 40],
with the exceptions of the PROTECT-CAD trial [35] that
demonstrated at 6 months a signiﬁcant improvement in
global LVEF in BM-treated patients (p = 0 044) versus
controls. Additionally, the study by van Ramshorst et al.
[40] conﬁrmed at 3 months an increase in LVEF in the cell-
treated group only (change, 3%; 95% CI, 0.5% to 4.7% versus
−1%; 95% CI, −2.1 to 1.1; p = 0 03).
In accordance with LVEF ﬁndings, a large proportion of
studies (62%) also reported negative outcomes associated
with LV volume measurements (Figure 3(d)).
Cumulatively, these data conﬁrm the well-known
assumption that the presence of a recovering ischemic
(hibernating) myocardium after perfusion restoration is
achievable in a minority of RA patients.
58%
42%
Myocardial perfusion (n = 24)
Positive
Negative
(a)
76%
24%
Functional capacity (n = 17) 
Positive
Negative
(b)
48%
52%
LV ejection fraction (n = 21)
Positive
Negative
(c)
38%
62%
LV volumes (n = 13)
Positive
Negative
(d)
Figure 3: Indices of myocardial perfusion, functional capacity, and cardiac function used to evaluate the eﬀect of cardiac cell-based therapy in
patients with RA. Positive and negative study outcomes have been deﬁned according to statistical signiﬁcance. The number of studies in the
analysis is indicated between brackets.
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3. Future Perspectives
Is there a chance for cardiac cell-based therapy to be
approved as a new therapy for RA? Overall, although
extremely demanding, RA is undoubtedly, among cardiac
conditions, the one in which cardiac cell-based therapy has
shown very promising outcomes. Indeed, a consistent body
of published trials cumulatively indicated that, although hard
clinical endpoint has not been reached so far, cardiac cell-
based therapy may increase the functional/perfusion status
in a subset of RA patients as well as in a vast proportion of
the quality of life, signiﬁcantly reducing angina symptoms
and antiangina medication usages.
Consistently, meta-analyses published to date showed
that cardiac cell-based therapy has a clinically relevant impact
over standard care [9–11]. Unfortunately and importantly,
pivotal trials have failed to provide a deﬁnitive response so
far, essentially due to strategically driven discontinuation of
patient recruitment before reaching the prespeciﬁed sample
size [12], low enrolment rates [13], or safety concerns [14].
Despite this, given the paucity of eﬀective therapeutics, along
with the extremely demanding clinical need, we consider car-
diac cell-based therapy has a viable treatment option in RA
for an addition to the therapeutic armamentarium of invasive
cardiologists. It is worth noting that, using autologous BM-
derived cells, intramyocardial cell delivery has been recently
cleared for hospital-based reimbursement (Heart Centrum
Leiden, Netherlands) as a percutaneous therapeutic strategy
in the context of RA (code 979001088).
3.1. Novel Cell Types and Allogeneic Setting. Interestingly,
alternative cell therapeutics and “oﬀ-the-shelf” settings are
currently under investigation to overcome hurdles related
to the lack of potency and cell impairments due to age and
risk factors. For example, the “Safety and Eﬃcacy of Human
Umbilical-Cord-derived Mesenchymal Stem Cell Transplan-
tation in Ischemic Cardiomyopathy” (UCMSC-Heart trial,
NCT02439541) is currently recruiting patients with chronic
heart ischemia and maximal tolerable angina to study the
eﬀect of the intracoronary infusion of MSC derived from
umbilical cord blood (1× 107). In this study, the primary
outcome is safety in terms of MACE in the ﬁrst year after
treatment while secondary outcomes are exercise time, perfu-
sion at SPECT, LVEF measured by echocardiography, and
clinical improvements. MSC are also studied in the “MESen-
chymal cell therapy And Myocardial Ischemia with
decreased left ventricular function” program (MESAMI2
trial, NCT02462330). The major aim of this project is to eval-
uate the eﬀect of intramyocardial administration of autolo-
gous BM-derived MSC (preconditioned with the pineal
hormone melatonin) using the NOGA XP system in patients
suﬀering from chronic ischemic cardiomyopathy with a
NYHA class II-IV and/or angina CCS class III-IV.
4. Conclusions
In this review, we have provided a comprehensive outlook on
the status of the cardiac cell-based therapy ﬁeld in the RA
context. Although available data are still inconclusive as for
deﬁnitive eﬃcacy, we acknowledge signals are present, as dis-
cussed in this review, that imply this strategy is the most
valuable advanced treatment option, as a tool to ameliorate
prognosis “quad vitam and valitudinem” in the therapeutic
algorithm of patients suﬀering for RA.
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